NO302574B1 - Indolkarbazolimider og deres anvendelse - Google Patents

Indolkarbazolimider og deres anvendelse

Info

Publication number
NO302574B1
NO302574B1 NO944564A NO944564A NO302574B1 NO 302574 B1 NO302574 B1 NO 302574B1 NO 944564 A NO944564 A NO 944564A NO 944564 A NO944564 A NO 944564A NO 302574 B1 NO302574 B1 NO 302574B1
Authority
NO
Norway
Prior art keywords
diseases
general formula
well
heart
immune
Prior art date
Application number
NO944564A
Other languages
English (en)
Norwegian (no)
Other versions
NO944564D0 (no
NO944564L (no
Inventor
Juergen Kleinschroth
Christoph Schaechtele
Johannes Hartenstein
Claus Rudolph
Hubert Barth
Julian Aranda
Hans-Juergen Betche
Original Assignee
Goedecke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goedecke Ag filed Critical Goedecke Ag
Publication of NO944564D0 publication Critical patent/NO944564D0/no
Publication of NO944564L publication Critical patent/NO944564L/no
Publication of NO302574B1 publication Critical patent/NO302574B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO944564A 1992-05-30 1994-11-29 Indolkarbazolimider og deres anvendelse NO302574B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4217964A DE4217964A1 (de) 1992-05-30 1992-05-30 Indolocarbazol-Imide und deren Verwendung
PCT/EP1993/001347 WO1993024491A1 (de) 1992-05-30 1993-05-28 Indolocarbazol-imide und deren verwendung

Publications (3)

Publication Number Publication Date
NO944564D0 NO944564D0 (no) 1994-11-29
NO944564L NO944564L (no) 1995-01-30
NO302574B1 true NO302574B1 (no) 1998-03-23

Family

ID=6460104

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944564A NO302574B1 (no) 1992-05-30 1994-11-29 Indolkarbazolimider og deres anvendelse

Country Status (18)

Country Link
US (2) US5883114A (ja)
EP (1) EP0642513B1 (ja)
JP (2) JP3587522B2 (ja)
KR (1) KR950701811A (ja)
AT (1) ATE195315T1 (ja)
AU (1) AU687350B2 (ja)
CA (1) CA2135768C (ja)
CZ (1) CZ295394A3 (ja)
DE (2) DE4217964A1 (ja)
DK (1) DK0642513T3 (ja)
ES (1) ES2152252T3 (ja)
FI (1) FI945625A (ja)
HU (1) HUT71102A (ja)
NO (1) NO302574B1 (ja)
NZ (1) NZ253090A (ja)
RU (1) RU2126007C1 (ja)
SK (1) SK146394A3 (ja)
WO (1) WO1993024491A1 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
EP0610519B1 (en) * 1992-09-02 1999-12-01 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv drug
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
DK0695755T3 (da) * 1994-08-04 1999-06-28 Hoffmann La Roche Pyrrolocarbazoler
WO1997041854A1 (en) * 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91498A1 (es) * 1996-07-29 1998-12-22 Hoffmann La Roche Pirroles sustituidos
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
ES2189597B2 (es) * 2000-07-18 2004-06-16 Fundacion Universitaria San Pablo-Ceu Derivados de 12,13-dihidro-5h-indolo(2,3-a)pirrolo(3,4-c)carbazol-5,7(6h)-diona como agentes antineoplasicos.
DK1325011T3 (da) 2000-09-29 2004-08-16 Lilly Co Eli Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
KR100446090B1 (ko) * 2000-10-19 2004-08-30 주식회사 엘컴사이언스 사우로락탐계 알카로이드의 퇴행성 뇌신경계 질환의 예방과 치료제로서의 용도 및 이 화합물을 유효성분으로 함유하는 약학적 제제
WO2002048166A1 (en) 2000-10-31 2002-06-20 Advanced Life Sciences, Inc. Indolocarbazole anticancer agents and methods of using them
US7122526B2 (en) * 2000-10-31 2006-10-17 Nanosphere, Inc. Indolocarbazole anticancer agents and methods of using same
CA2444501C (en) 2001-04-11 2009-11-17 Idenix (Cayman) Limited Phenylindoles for the treatment of hiv
WO2003022861A1 (en) * 2001-09-13 2003-03-20 Bristol-Myers Squibb Company Process for the preparation of rebeccamycin and analogs thereof
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
FR2833840B1 (fr) * 2001-12-21 2010-06-18 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
US7365090B2 (en) * 2002-08-07 2008-04-29 Idenix Pharmaceuticals, Inc. Substituted phenylindoles for the treatment of HIV
CA2522712A1 (en) * 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Nerve regenerating drug
SG155939A1 (en) 2004-09-17 2009-10-29 Idenix Pharmaceuticals Inc Phosphoindoles as hiv inhibitors
FR2879100B1 (fr) * 2004-12-09 2007-07-06 Lionel Bueno Compositions pour le traitement des pathologies oculaires de surface et de la retine
US20070249590A1 (en) * 2005-10-28 2007-10-25 Wilson Lawrence J Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
EA016267B1 (ru) 2006-09-29 2012-03-30 Айденикс Фармасьютикалз, Инк. Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
EP2047849A1 (en) * 2007-10-08 2009-04-15 KTB Tumorforschungsgesellschaft mbH Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムＩｎｓｅｒｍ 神経筋接合部関連疾患の処置方法
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
CN107556323B (zh) * 2017-08-30 2019-09-20 浙江大学 一种氨基取代星孢菌素类化合物及其制备方法和应用
CN112739345A (zh) * 2017-11-06 2021-04-30 斯奈普生物公司 Pim激酶抑制剂组合物，方法和其用途
CN113980000B (zh) * 2021-12-30 2022-05-20 北京鑫开元医药科技有限公司 甲基酮类衍生物、制备方法、药物组合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217885A (en) * 1989-03-23 1993-06-08 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C
JP3010675B2 (ja) * 1989-03-23 2000-02-21 萬有製薬株式会社 抗腫瘍性物質ｂｅ―１３７９３ｃ
JP3064416B2 (ja) * 1990-05-11 2000-07-12 萬有製薬株式会社 抗腫瘍性物質ｂｅ―１３７９３ｃ誘導体
EP0630242B1 (en) * 1992-03-20 1999-01-20 The Wellcome Foundation Limited Further indole derivatives with antiviral activity

Also Published As

Publication number Publication date
ES2152252T3 (es) 2001-02-01
KR950701811A (ko) 1995-05-17
DE4217964A1 (de) 1993-12-02
JP3587522B2 (ja) 2004-11-10
NO944564D0 (no) 1994-11-29
AU4319493A (en) 1993-12-30
JP2004026842A (ja) 2004-01-29
JPH07508268A (ja) 1995-09-14
FI945625A0 (fi) 1994-11-29
HUT71102A (en) 1995-11-28
CZ295394A3 (en) 1995-03-15
FI945625A (fi) 1994-11-29
CA2135768C (en) 2004-11-23
CA2135768A1 (en) 1993-12-01
US5883114A (en) 1999-03-16
SK146394A3 (en) 1995-08-09
ATE195315T1 (de) 2000-08-15
US5945440A (en) 1999-08-31
EP0642513B1 (de) 2000-08-09
EP0642513A1 (de) 1995-03-15
RU94046306A (ru) 1996-10-27
NZ253090A (en) 1997-02-24
AU687350B2 (en) 1998-02-26
RU2126007C1 (ru) 1999-02-10
DK0642513T3 (da) 2001-01-02
DE59310085D1 (de) 2000-09-14
HU9403419D0 (en) 1995-02-28
WO1993024491A1 (de) 1993-12-09
NO944564L (no) 1995-01-30

Similar Documents

Publication Publication Date Title
NO302574B1 (no) Indolkarbazolimider og deres anvendelse
BG86132A (bg) Производни на пиридазинамин
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
SE0104340D0 (sv) New compounds
HUT53902A (en) Process for producing maleimide derivatives and pharmaceutical compositions containing them as active components
DK602988D0 (da) Nukleosidderivater med antiviral virkning og laegemiddelpraeparat indeholdende saadanne forbindelser
FI913478A0 (fi) Diazinderivat.
GR3020866T3 (en) Indolocarbazole derivatives, processes for their preparation and their use
NO302523B1 (no) Heterosykliske forbindelser, farmasöytiske preparater som omfatter dem, og anvendelse av forbindelsene for fremstilling av medikamenter
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
AP9801286A0 (en) Therapeutic compounds.
AU584235B2 (en) New tricyclic compounds, processes for the preparation thereof and pharmaceutical compositions containing them
NO172640C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperazinderivater
CA2198010A1 (en) 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent
UA42693C2 (uk) Лікарський засіб для лікування інфекції лентивірусом, препарат для лікування людини, яка інфікована лентивірусом
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
MX9503363A (es) N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2000